The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5mg /day and 1mg /day) in active lupus arthritis patients. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. For Multiple Sclerosis.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01085084?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
